<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p55" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_55{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_55{left:341px;bottom:30px;}
#t3_55{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_55{left:377px;bottom:30px;}
#t5_55{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_55{left:540px;bottom:30px;}
#t7_55{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_55{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_55{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_55{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_55{left:285px;bottom:827px;letter-spacing:-0.24px;}
#tc_55{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_55{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_55{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_55{left:1098px;bottom:28px;letter-spacing:0.32px;}
#tg_55{left:36px;bottom:198px;}
#th_55{left:46px;bottom:192px;letter-spacing:0.13px;}
#ti_55{left:261px;bottom:192px;}
#tj_55{left:36px;bottom:181px;}
#tk_55{left:42px;bottom:176px;letter-spacing:0.13px;word-spacing:-0.06px;}
#tl_55{left:336px;bottom:176px;}
#tm_55{left:36px;bottom:165px;}
#tn_55{left:42px;bottom:159px;letter-spacing:0.11px;word-spacing:0.01px;}
#to_55{left:45px;bottom:142px;letter-spacing:0.12px;}
#tp_55{left:651px;bottom:142px;letter-spacing:0.13px;}
#tq_55{left:735px;bottom:142px;}
#tr_55{left:36px;bottom:131px;}
#ts_55{left:45px;bottom:125px;letter-spacing:0.12px;word-spacing:-0.03px;}
#tt_55{left:556px;bottom:125px;}
#tu_55{left:36px;bottom:114px;}
#tv_55{left:46px;bottom:108px;letter-spacing:0.12px;}
#tw_55{left:195px;bottom:778px;letter-spacing:0.44px;word-spacing:-0.9px;}
#tx_55{left:36px;bottom:567px;letter-spacing:-0.26px;}
#ty_55{left:36px;bottom:549px;letter-spacing:-0.09px;}
#tz_55{left:36px;bottom:530px;letter-spacing:-0.12px;}
#t10_55{left:36px;bottom:512px;letter-spacing:-0.1px;}
#t11_55{left:97px;bottom:520px;letter-spacing:-0.12px;}
#t12_55{left:195px;bottom:711px;letter-spacing:-0.09px;}
#t13_55{left:195px;bottom:692px;letter-spacing:-0.14px;}
#t14_55{left:195px;bottom:547px;letter-spacing:-0.09px;}
#t15_55{left:195px;bottom:529px;letter-spacing:-0.14px;}
#t16_55{left:195px;bottom:354px;letter-spacing:-0.09px;}
#t17_55{left:195px;bottom:336px;letter-spacing:-0.11px;}
#t18_55{left:348px;bottom:711px;letter-spacing:-0.1px;}
#t19_55{left:452px;bottom:718px;}
#t1a_55{left:348px;bottom:692px;letter-spacing:-0.09px;}
#t1b_55{left:348px;bottom:577px;letter-spacing:-0.13px;}
#t1c_55{left:372px;bottom:585px;}
#t1d_55{left:348px;bottom:559px;letter-spacing:-0.09px;}
#t1e_55{left:348px;bottom:540px;letter-spacing:-0.09px;}
#t1f_55{left:348px;bottom:522px;letter-spacing:-0.1px;}
#t1g_55{left:436px;bottom:530px;letter-spacing:-0.07px;}
#t1h_55{left:348px;bottom:504px;letter-spacing:-0.1px;}
#t1i_55{left:348px;bottom:412px;letter-spacing:-0.1px;}
#t1j_55{left:411px;bottom:419px;}
#t1k_55{left:348px;bottom:352px;letter-spacing:-0.1px;}
#t1l_55{left:348px;bottom:297px;letter-spacing:-0.09px;}
#t1m_55{left:348px;bottom:279px;letter-spacing:-0.1px;}
#t1n_55{left:1066px;bottom:411px;letter-spacing:-0.1px;}
#t1o_55{left:1066px;bottom:393px;letter-spacing:-0.09px;}
#t1p_55{left:1066px;bottom:375px;letter-spacing:-0.08px;}
#t1q_55{left:1066px;bottom:325px;letter-spacing:-0.09px;}
#t1r_55{left:1066px;bottom:307px;letter-spacing:-0.06px;}
#t1s_55{left:1066px;bottom:289px;letter-spacing:-0.08px;}
#t1t_55{left:1066px;bottom:270px;letter-spacing:-0.09px;}
#t1u_55{left:1066px;bottom:252px;letter-spacing:-0.25px;}
#t1v_55{left:471px;bottom:469px;letter-spacing:-0.1px;}
#t1w_55{left:471px;bottom:451px;letter-spacing:-0.09px;}
#t1x_55{left:626px;bottom:459px;}
#t1y_55{left:568px;bottom:318px;letter-spacing:-0.09px;}
#t1z_55{left:453px;bottom:377px;letter-spacing:-0.1px;}
#t20_55{left:453px;bottom:359px;letter-spacing:-0.09px;}
#t21_55{left:453px;bottom:340px;letter-spacing:-0.09px;}
#t22_55{left:519px;bottom:348px;}
#t23_55{left:568px;bottom:414px;letter-spacing:-0.09px;}
#t24_55{left:568px;bottom:395px;letter-spacing:-0.09px;}
#t25_55{left:817px;bottom:458px;letter-spacing:-0.13px;}
#t26_55{left:841px;bottom:465px;}
#t27_55{left:791px;bottom:414px;letter-spacing:-0.1px;}
#t28_55{left:959px;bottom:421px;letter-spacing:-0.09px;}
#t29_55{left:791px;bottom:395px;letter-spacing:-0.09px;}
#t2a_55{left:753px;bottom:346px;letter-spacing:-0.13px;}
#t2b_55{left:777px;bottom:353px;}
#t2c_55{left:753px;bottom:327px;letter-spacing:-0.06px;}
#t2d_55{left:753px;bottom:309px;letter-spacing:-0.1px;}
#t2e_55{left:753px;bottom:291px;letter-spacing:-0.13px;}
#t2f_55{left:777px;bottom:298px;letter-spacing:-0.09px;}
#t2g_55{left:1074px;bottom:636px;letter-spacing:-0.09px;word-spacing:-0.48px;}
#t2h_55{left:1074px;bottom:618px;letter-spacing:-0.08px;}
#t2i_55{left:1074px;bottom:599px;letter-spacing:-0.09px;}
#t2j_55{left:1074px;bottom:581px;letter-spacing:-0.25px;}
#t2k_55{left:516px;bottom:283px;letter-spacing:-0.35px;}
#t2l_55{left:572px;bottom:616px;letter-spacing:-0.1px;}
#t2m_55{left:572px;bottom:596px;letter-spacing:-0.09px;}
#t2n_55{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_55{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_55{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_55{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_55{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_55{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_55{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_55{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_55{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_55{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_55{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sa_55{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_55{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sc_55{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sd_55{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts55" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg55Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg55" style="-webkit-user-select: none;"><object width="1210" height="935" data="55/55.svg" type="image/svg+xml" id="pdf55" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_55" class="t s0_55">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_55" class="t s1_55">® </span>
<span id="t3_55" class="t s0_55">(NCCN </span>
<span id="t4_55" class="t s1_55">® </span>
<span id="t5_55" class="t s0_55">), All rights reserved. NCCN Guidelines </span>
<span id="t6_55" class="t s1_55">® </span>
<span id="t7_55" class="t s0_55">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_55" class="t s2_55">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_55" class="t s2_55">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_55" class="t s3_55">NCCN Guidelines Version 4.2024 </span>
<span id="tb_55" class="t s3_55">Cancer of the Supraglottic Larynx </span>
<span id="tc_55" class="t s4_55">NCCN Guidelines Index </span>
<span id="td_55" class="t s4_55">Table of Contents </span>
<span id="te_55" class="t s4_55">Discussion </span>
<span id="tf_55" class="t s5_55">SUPRA-7 </span>
<span id="tg_55" class="t s6_55">h </span>
<span id="th_55" class="t s7_55">Principles of Surgery (SURG-A)</span><span id="ti_55" class="t s8_55">. </span>
<span id="tj_55" class="t s6_55">i </span>
<span id="tk_55" class="t s7_55">Principles of Radiation Therapy (SUPRA-A)</span><span id="tl_55" class="t s8_55">. </span>
<span id="tm_55" class="t s6_55">j </span>
<span id="tn_55" class="t s8_55">Adverse pathologic features: extranodal extension, positive margins, close margins, pT3 or pT4 primary, </span>
<span id="to_55" class="t s8_55">pN2 or pN3 nodal disease, perineural invasion, vascular invasion, and lymphatic invasion </span><span id="tp_55" class="t s7_55">(Discussion)</span><span id="tq_55" class="t s8_55">. </span>
<span id="tr_55" class="t s6_55">k </span>
<span id="ts_55" class="t s7_55">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="tt_55" class="t s8_55">. </span>
<span id="tu_55" class="t s6_55">o </span>
<span id="tv_55" class="t s9_55">In randomized clinical trials, assessment of response has been done after 2 or 3 cycles. </span>
<span id="tw_55" class="t s5_55">RESPONSE ASSESSMENT </span>
<span id="tx_55" class="t s5_55">Response after </span>
<span id="ty_55" class="t s5_55">induction </span>
<span id="tz_55" class="t s5_55">chemo- </span>
<span id="t10_55" class="t s5_55">therapy </span>
<span id="t11_55" class="t sa_55">k,o </span>
<span id="t12_55" class="t s5_55">Primary site: </span>
<span id="t13_55" class="t s5_55">CR </span>
<span id="t14_55" class="t s5_55">Primary site: </span>
<span id="t15_55" class="t s5_55">PR </span>
<span id="t16_55" class="t s5_55">Primary site: </span>
<span id="t17_55" class="t s5_55">&lt; PR </span>
<span id="t18_55" class="t sb_55" data-mappings='[[2,"fi"]]'>Deﬁnitive RT </span>
<span id="t19_55" class="t sa_55">i </span>
<span id="t1a_55" class="t s5_55">(category 1) </span>
<span id="t1b_55" class="t s5_55">RT </span>
<span id="t1c_55" class="t sa_55">i </span>
<span id="t1d_55" class="t s5_55">(category 1) </span>
<span id="t1e_55" class="t s5_55">or systemic </span>
<span id="t1f_55" class="t s5_55">therapy/RT </span>
<span id="t1g_55" class="t sa_55">i,k </span>
<span id="t1h_55" class="t s5_55">(category 2B) </span>
<span id="t1i_55" class="t s5_55">Surgery </span>
<span id="t1j_55" class="t sa_55">h </span>
<span id="t1k_55" class="t s5_55">or </span>
<span id="t1l_55" class="t s5_55">Unresectable </span>
<span id="t1m_55" class="t s5_55">nodal disease </span>
<span id="t1n_55" class="t s5_55">Follow-up </span>
<span id="t1o_55" class="t sc_55">(FOLL-A, 1 </span>
<span id="t1p_55" class="t sc_55">of 2) </span>
<span id="t1q_55" class="t s5_55">Recurrent </span>
<span id="t1r_55" class="t s5_55">or </span>
<span id="t1s_55" class="t s5_55">persistent </span>
<span id="t1t_55" class="t s5_55">disease </span>
<span id="t1u_55" class="t sc_55">(ADV-3) </span>
<span id="t1v_55" class="t s5_55">No adverse </span>
<span id="t1w_55" class="t s5_55">pathologic features </span>
<span id="t1x_55" class="t sa_55">j </span>
<span id="t1y_55" class="t s5_55">Other risk features </span>
<span id="t1z_55" class="t s5_55">Adverse </span>
<span id="t20_55" class="t s5_55">pathologic </span>
<span id="t21_55" class="t s5_55">features </span>
<span id="t22_55" class="t sa_55">j </span>
<span id="t23_55" class="t s5_55">Extranodal extension </span>
<span id="t24_55" class="t s5_55">and/or positive margin </span>
<span id="t25_55" class="t s5_55">RT </span>
<span id="t26_55" class="t sa_55">i </span>
<span id="t27_55" class="t s5_55">Systemic therapy/RT </span>
<span id="t28_55" class="t sa_55">i,k </span>
<span id="t29_55" class="t s5_55">(category 1) </span>
<span id="t2a_55" class="t s5_55">RT </span>
<span id="t2b_55" class="t sa_55">i </span>
<span id="t2c_55" class="t s5_55">or </span>
<span id="t2d_55" class="t s5_55">Consider systemic therapy/ </span>
<span id="t2e_55" class="t s5_55">RT </span>
<span id="t2f_55" class="t sa_55">i,k </span>
<span id="t2g_55" class="t s5_55">Recurrent or </span>
<span id="t2h_55" class="t s5_55">persistent </span>
<span id="t2i_55" class="t s5_55">disease </span>
<span id="t2j_55" class="t sc_55">(ADV-3) </span>
<span id="t2k_55" class="t sc_55">ADV-1 </span>
<span id="t2l_55" class="t sc_55">Post Systemic Therapy/RT or RT </span>
<span id="t2m_55" class="t sc_55">Neck Evaluation (FOLL-A, 2 of 2) </span>
<span id="t2n_55" class="t sd_55">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
